Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma

SUGURU SHIROTAKE, YU MIYAMA, YASUTAKA BABA, HIROYUKI TAJIMA, YOSHITAKA OKADA, KEN NAKAZAWA, YOKO USAMI, MASANORI YASUDA, DAISUKE IGARASHI, GO KANEKO, KENT KANAO, MASAFUMI OYAMA and KOSHIRO NISHIMOTO
Anticancer Research May 2022, 42 (5) 2727-2735; DOI: https://doi.org/10.21873/anticanres.15751
SUGURU SHIROTAKE
1Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ss6001@5931.saitama-med.ac.jp
YU MIYAMA
2Department of Diagnostic Pathology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUTAKA BABA
3Department of Diagnostic Radiology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYUKI TAJIMA
3Department of Diagnostic Radiology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHITAKA OKADA
3Department of Diagnostic Radiology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEN NAKAZAWA
3Department of Diagnostic Radiology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOKO USAMI
3Department of Diagnostic Radiology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASANORI YASUDA
2Department of Diagnostic Pathology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAISUKE IGARASHI
1Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GO KANEKO
1Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENT KANAO
1Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAFUMI OYAMA
1Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOSHIRO NISHIMOTO
1Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: CheckMate 214 study revealed that nivolumab plus ipilimumab combination therapy showed a strong and durable effect compared to sunitinib for patients with advanced renal cell carcinoma (aRCC). Most of the patients underwent previous nephrectomy before systemic treatment. We retrospectively investigated the clinical outcomes of Japanese patients treated with cytoreductive nephrectomy following nivolumab plus ipilimumab for aRCC. Patients and Methods: Seventy-nine patients were treated with systemic therapy for aRCC between October 2018 and August 2021 at the Saitama Medical University International Medical Center. Ten of 61 patients treated with nivolumab plus ipilimumab underwent cytoreductive nephrectomy after the combined immunotherapy. Results: The median overall survival and progression-free survival were 24.3 and 15.9 months, respectively. The objective response rate was 50.8%; 9.8% of patients had a complete response, and the median time to objective response was 3.2 (range=1.3-19.7) months. The estimated percentage of patients who sustained an objective response at 30 months was 73.0%. Twenty-three patients (74%) in the complete or partial response (CR/PR) group, 11 patients (52%) in the stable disease (SD) group, and two patients (22%) in the progressive disease (PD) group had immune-related adverse events of grade 3 or higher, respectively. For all 10 patients, cytoreductive nephrectomy following nivolumab plus ipilimumab treatment were completed safely. Three patients achieved a pathological complete response without viable cancer cells. Only two patients had residual lesions on images after deferred cytoreductive nephrectomy; the remaining patients achieved radiological CR. Conclusion: Cytoreductive nephrectomy after nivolumab plus ipilimumab treatment could be useful in a limited number of cases, possibly resulting in curative nephrectomy due to the durable therapeutic effect of immunotherapy.

Key Words:
  • Renal cell carcinoma
  • nivolumab plus ipilimumab
  • cytoreductive nephrectomy
  • Received January 29, 2022.
  • Revision received February 23, 2022.
  • Accepted March 22, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (5)
Anticancer Research
Vol. 42, Issue 5
May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
SUGURU SHIROTAKE, YU MIYAMA, YASUTAKA BABA, HIROYUKI TAJIMA, YOSHITAKA OKADA, KEN NAKAZAWA, YOKO USAMI, MASANORI YASUDA, DAISUKE IGARASHI, GO KANEKO, KENT KANAO, MASAFUMI OYAMA, KOSHIRO NISHIMOTO
Anticancer Research May 2022, 42 (5) 2727-2735; DOI: 10.21873/anticanres.15751

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Impact of Cytoreductive Nephrectomy Following Nivolumab Plus Ipilimumab Therapy for Patients With Advanced Renal Cell Carcinoma
SUGURU SHIROTAKE, YU MIYAMA, YASUTAKA BABA, HIROYUKI TAJIMA, YOSHITAKA OKADA, KEN NAKAZAWA, YOKO USAMI, MASANORI YASUDA, DAISUKE IGARASHI, GO KANEKO, KENT KANAO, MASAFUMI OYAMA, KOSHIRO NISHIMOTO
Anticancer Research May 2022, 42 (5) 2727-2735; DOI: 10.21873/anticanres.15751
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment
  • Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study
Show more Clinical Studies

Similar Articles

Keywords

  • Renal cell carcinoma
  • nivolumab plus ipilimumab
  • cytoreductive nephrectomy
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire